Literature DB >> 17559344

Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.

Zeruesenay Desta1, Tanja Saussele, Bryan Ward, Julia Blievernicht, Lang Li, Kathrin Klein, David A Flockhart, Ulrich M Zanger.   

Abstract

OBJECTIVES: To determine the influence of cytochrome P450 2B6 (CYP2B6) genotype on the rate of oxidative efavirenz metabolism in human liver microsomes. MATERIALS &
METHODS: Formation rates of 8-hydroxyefavirenz, 7-hydroxyefavirenz and 8,14-dihydroxyefavirenz were determined in vitro with efavirenz as a substrate (10 microM) in a large panel of human liver microsomes (n = 87) that were genotyped for variants of the CYP2B6 gene and phenotyped for CYP2B6 protein expression and bupropion hydroxylation.
RESULTS: Efavirenz 8-hydroxylation, the major route of efavirenz clearance, was detected in all samples, exhibiting an overall interindividual variability of 44.7-fold; 8,14-dihydroxyefavirenz and 7-hydroxyefavirenz were also detected in most samples. The formation rate of 8-hydroxyefavirenz correlated significantly with CYP2B6 protein (Spearman's r(S) = 0.54; p < 0.0001) and bupropion hydroxylase activity (r(S) = 0.73; p < 0.0001). Compared with the *1/*1 genotype, efavirenz 8-hydroxylation was significantly lower in samples with *1/*6 and *6/*6 genotype, which also had significantly decreased CYP2B6 protein (Mann-Whitney test, p < 0.05). A decrease in CYP2B6 protein was also observed in samples with *1/*5 and *5/*6 genotypes, but this did not result in significant reduction of efavirenz metabolism, probably due to differences in specific activity of the protein variants. Lower CYP2B6 protein and activity, as well as efavirenz 8-hydroxylation was also found in several samples with rarer genotypes. We found no effect of gender and age on any of the phenotypes tested, but prior exposure to carbamazepine markedly increased CYP2B6 protein expression and activity as well as efavirenz 8-hydroxylation.
CONCLUSIONS: We have shown that CYP2B6 genetic polymorphism markedly influences the metabolism of efavirenz in human liver microsomes. Importantly, the CYP2B6*6 allele harboring the SNPs c.516G>T [Q172H] and c.785A>G [K262R] was significantly associated with a pronounced decrease in CYP2B6 expression and activity, as well as a low rate of efavirenz 8-hydroxylation. These results represent a first step towards elucidating the mechanism by which this allele identifies patients exhibiting very high efavirenz plasma concentrations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17559344     DOI: 10.2217/14622416.8.6.547

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  97 in total

1.  Bioactivation of chlorpyrifos by CYP2B6 variants.

Authors:  Alice L Crane; Kathrin Klein; James R Olson
Journal:  Xenobiotica       Date:  2012-07-10       Impact factor: 1.908

2.  PharmGKB summary: very important pharmacogene information for CYP2B6.

Authors:  Caroline F Thorn; Jatinder K Lamba; Vishal Lamba; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-08       Impact factor: 2.089

3.  Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.

Authors:  Evan T Ogburn; David R Jones; Andrea R Masters; Cong Xu; Yingying Guo; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2010-03-24       Impact factor: 3.922

4.  Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.

Authors:  V Michaud; E Ogburn; N Thong; A O Aregbe; T C Quigg; D A Flockhart; Z Desta
Journal:  Clin Pharmacol Ther       Date:  2012-02-08       Impact factor: 6.875

5.  Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review.

Authors:  Daniel Atwine; Maryline Bonnet; Anne-Marie Taburet
Journal:  Br J Clin Pharmacol       Date:  2018-05-22       Impact factor: 4.335

Review 6.  Pharmacogenomic discovery using cell-based models.

Authors:  Marleen Welsh; Lara Mangravite; Marisa Wong Medina; Kelan Tantisira; Wei Zhang; R Stephanie Huang; Howard McLeod; M Eileen Dolan
Journal:  Pharmacol Rev       Date:  2009-12       Impact factor: 25.468

Review 7.  Efavirenz in the therapy of HIV infection.

Authors:  Natella Y Rakhmanina; John N van den Anker
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-01       Impact factor: 4.481

8.  CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.

Authors:  Awewura Kwara; Margaret Lartey; Kwamena W C Sagoe; Ernest Kenu; Michael H Court
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

Review 9.  Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.

Authors:  Awewura Kwara; Geetha Ramachandran; Soumya Swaminathan
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-01       Impact factor: 4.481

10.  Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.

Authors:  Evan D Kharasch; Darain Mitchell; Rebecka Coles; Roberto Blanco
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.